SCHEMBL1840311

SCHEMBL1840311

COC(=O)[C@H](CCCCN)NC(=O)OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 3/20 0.61
SIRT1 Q96EB6 3/20 0.61
SIRT3 Q9NTG7 3/20 0.61
ITGB3 P05106 4/20 0.57
ITGA2B P08514 4/20 0.57
PRSS1 P07477 2/20 0.57
PRSS2 P07478 2/20 0.57
PRSS3 P35030 2/20 0.57
TPSAB1 Q15661 2/20 0.57
KYNU Q16719 1/20 0.57
TLR2 O60603 2/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
DPP4 P27487 1/20 0.56
ECE1 P42892 1/20 0.55
CPB1 P15086 1/20 0.55
CPB2 Q96IY4 1/20 0.55
ALDH1A1 P00352 1/20 0.55
ALOX15 P16050 1/20 0.55
CTSL P07711 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840309 1.00 SIRT2 (0.61) SIRT2SIRT1SIRT3ITGB3ITGA2B
SCHEMBL6477219 1.00 SIRT2 (0.61) SIRT2SIRT1SIRT3ITGB3ITGA2B
Hydrochloric Acid SCHEMBL3952159 0.99 SIRT2 (0.60) SIRT2SIRT1SIRT3ITGB3ITGA2B
Hydrochloric Acid SCHEMBL3952162 0.99 SIRT2 (0.60) SIRT2SIRT1SIRT3ITGB3ITGA2B
Hydrochloric Acid SCHEMBL6528872 0.99 SIRT2 (0.60) SIRT2SIRT1SIRT3ITGB3ITGA2B
SCHEMBL8447229 0.96 SIRT2 (0.59) SIRT2SIRT1SIRT3ITGB3ITGA2B
SCHEMBL8447232 0.96 SIRT2 (0.59) SIRT2SIRT1SIRT3ITGB3ITGA2B
Hydrochloric Acid SCHEMBL6236103 0.95 SIRT2 (0.58) SIRT2SIRT1SIRT3ITGB3ITGA2B
Hydrochloric Acid SCHEMBL6236109 0.95 SIRT2 (0.58) SIRT2SIRT1SIRT3ITGB3ITGA2B
SCHEMBL8386880 0.93 SIRT2 (0.67) SIRT2SIRT1SIRT3KYNUCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4605409-A2 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2025-08-27 EP disclosed
US-20250243219-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CYPRALIS LIMITED (GB) 2025-07-31 US disclosed
US-20250161468-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4526308-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF Cypralis Limited (GB) 2025-03-26 EP disclosed
US-20240390507-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2024-11-28 US disclosed
US-20240218021-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-07-04 US disclosed
WO-2024086814-A2 CYCLIN INHIBITORS CIRCLE PHARMA, INC. (US) 2024-04-25 WO disclosed
CN-117460743-A Small molecule VE-PTP inhibitors 曼宁研究公司 2024-01-26 CN disclosed
WO-2023223057-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CYPRALIS LIMITED (GB) 2023-11-23 WO disclosed
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS AJINOMOTO CO., INC. (JP) 2023-07-06 US disclosed
CN-1101908-A Angiotensin II antagonists LILLY CO ELI (US) 1995-04-26 CN disclosed
EP-0644887-A1 PROCESS FOR THE PREPARATION OF CLAVULANIC ACID. SMITHKLINE BEECHAM PLC (GB) 1995-03-29 EP disclosed
EP-0288278-B1 Chemical derivatives of GHL-CU PROCYTE CORP (US) 1994-03-30 EP disclosed
WO-1993025557-A1 PROCESS FOR THE PREPARATION OF CLAVULANIC ACID SMITHKLINE BEECHAM PLC (GB) 1993-12-23 WO disclosed
EP-0574174-A2 Angiotensin II antagonists ELI LILLY AND COMPANY (US) 1993-12-15 EP disclosed
EP-0293071-B1 REDOX AMINO ACIDS AND PEPTIDES CONTAINING THEM UNIVERSITY OF FLORIDA (US) 1993-09-01 EP disclosed
EP-0293071-A1 Redox amino acids and peptides containing them UNIVERSITY OF FLORIDA (US) 1988-11-30 EP disclosed
EP-0288278-A2 Chemical derivatives of GHL-CU PROCYTE CORPORATION (US) 1988-10-26 EP disclosed
EP-0190736-A2 Chemical derivatives of GHL-Cu PROCYTE CORPORATION (US) 1986-08-13 EP disclosed
EP-0175180-A1 Histargin-related compounds, a process for their preparation and their use as medicaments MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 1986-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS DAO, ALAD, BCAT1 SIRT2 3556/4885SIRT1 2971/4885SIRT3 4204/4885
US-20240218021-A1 CYCLIN INHIBITORS CCNI, CCNC, CDK2 SIRT2 2480/4885SIRT1 1851/4885SIRT3 2971/4885
US-20250161468-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRL1 SIRT2 4193/4885SIRT1 2554/4885SIRT3 3275/4885
US-20240390507-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRL1 SIRT2 4193/4885SIRT1 2554/4885SIRT3 3275/4885
US-20250243219-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CASP3, TNNC1, BAD SIRT2 1103/4885SIRT1 453/4885SIRT3 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.